Education
About Us
Working with TipRanks
Follow Us
Vericel Corporation (VCEL)
:VCEL
VCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$33.09 - $63.00
Previous CloseN/A
Volume83.17K
Average Volume (3M)616.26K
Market Cap
$1.87B
Enterprise Value$2.13B
Total Cash (Recent Filing)$116.88M
Total Debt (Recent Filing)$101.54M
Price to Earnings (P/E)297.0
Beta1.12
Next Earnings
Nov 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding50,460,205
10 Day Avg. Volume525,296
30 Day Avg. Volume616,259
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda131.44
Forecast
1Y Price Target
$52.63Price Target Upside42.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
InnovationArthro opens use of MACI by arthroscopic-only surgeons, potentially expanding the target base significantly.
Product DevelopmentFDA clearance for the Phase 3 MASCOT study with MACI ankle indicates progress in product development and potential future opportunities.
Surgeon Base ExpansionThe expansion of the MACI surgeon customer base and growth in biopsies suggests increasing demand and market penetration.
Bears Say
Revenue ConcernsShare pressure has been driven by concerns surrounding the revenue acceleration required to meet Street estimates.
Sales PerformanceVCEL reported 2Q25 sales of $63.2mn, which is 2% below consensus of $64.5mn.
Valuation ConcernsValuation now sits meaningfully below historical levels, with VCEL's current NTM EV/Sales multiple relative to the IHI of 1.1x near its 3Y trough of 0.9x, which is believed to reflect the variability in pro forma Burn Care numbers.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $33.09 and its highest was $63.00 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $1.87B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Nov 06, 2025 which is in 73 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on Jul 31, 2025. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.032 by $0.022.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 50,460,205 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.032. Following the earnings report the stock price went down -14.068%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.63 (42.13% Upside)
$52.63 (42.13% Upside)
Blogger Sentiment
Bullish
VCEL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.04%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation (VCEL) is a biotechnology company focused on developing and commercializing advanced cell therapies for the treatment of severe diseases and conditions. The company operates primarily in the regenerative medicine sector, specializing in products for the treatment of sports medicine and critical limb ischemia. Vericel's core products include MACI (Matrix Autologous Cultured Chondrocytes) for cartilage repair and Epicel, a cultured epidermal autograft for the treatment of burns.
VCEL Company Deck
VCEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth across key segments and robust profitability metrics. Despite a few challenges such as Epicel cancellations and adjusted guidance for Burn Care, the overall business outlook remains positive with promising growth indicators, especially in the MACI segment.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$52.63
▲(42.13% Upside)
Technical Analysis
Ligand Pharma
―
Veracyte
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Ownership Overview
1.06% Insiders
36.95% Mutual Funds
4.62% Other Institutional Investors
35.41% Public Companies and
Individual Investors